Pharmaceuticals

Global Postherpetic Neuralgia (PHN) Market Projected to Expand at 6.6% CAGR by 2029

November 14, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Postherpetic Neuralgia (PHN) Market Size Likely To Evolve From 2025 Through 2034?

The market size for postherpetic neuralgia (phn) has shown robust growth over recent years. It is anticipated to expand from $0.72 billion in 2024 to $0.77 billion in 2025, at a compound annual growth rate (CAGR) of 7.0%. The expansion observed in the past can be linked to an increase in the incidence of herpes zoster infections, an expanding older adult population, heightened awareness among both patients and healthcare providers, a growing need for effective neuropathic pain management strategies, and rising healthcare spending.

The postherpetic neuralgia (PHN) market size is set to experience significant expansion in the coming years. It is projected to reach $0.99 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.6%. This anticipated growth can be attributed to the increasing utilization of antiviral medications and vaccines, the rising prevalence of chronic pain disorders, the growing adoption of advanced drug delivery systems, an increase in clinical trials and research and development investments, and more regulatory approvals for new therapeutics. Prominent trends throughout the forecast period include advancements in neuropathic pain research, innovations in drug delivery technologies, technology-driven diagnostic tools, the integration of artificial intelligence in clinical trials, and progress in non-opioid pain management alternatives.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

Which Drivers Are Impacting The Postherpetic Neuralgia (PHN) Market?

The growing occurrence of chronic pain conditions is projected to boost the expansion of the postherpetic neuralgia (PHN) market in the future. Chronic pain is defined as ongoing or recurrent discomfort enduring for over three months, frequently extending past the typical duration of an ailment or injury, thereby impacting an individual’s daily activities and overall well-being. The widespread nature of chronic pain stems from the aging demographic, given that seniors are more susceptible to degenerative conditions such as arthritis and neuropathy, which result in persistent discomfort. Postherpetic neuralgia is valuable in chronic pain research, offering a distinct model for investigating nerve-related pain mechanisms and assessing long-term therapeutic approaches. For instance, a January 2024 report from the UK government’s Office for Health Improvement and Disparities indicated that approximately 18.4% of individuals aged 16 and above reported a long-term musculoskeletal (MSK) condition in 2023, an increase from 17.6% in 2022. Consequently, the rising prevalence of chronic pain conditions is fueling the expansion of the postherpetic neuralgia (PHN) market.

What Are The Leading Segments Analyzed In The Postherpetic Neuralgia (PHN) Market?

The postherpetic neuralgia (PHN) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Nicotine Patches, Hormone Replacement Therapy Patches, Analgesic Patches, Orthopedic Support Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

What Key Innovation Trends Are Fueling Advancements In The Postherpetic Neuralgia (PHN) Market?

Leading companies operating in the postherpetic neuralgia (PHN) market are actively pursuing regulatory clearances to expand their product portfolios, gain a competitive advantage, and address the significant unmet clinical need for more effective and tolerable treatments. Regulatory approvals denote the official permissions granted by government health authorities that allow a drug or therapy to be legally marketed and utilized for a specific medical condition. For instance, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, secured final United States Food and Drug Administration approval to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, indicated for the management of postherpetic neuralgia (PHN). These gabapentin tablets are intended for treating PHN, a form of neuropathic pain resulting from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing commences at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as needed for pain relief.

Which Major Industry Participants Are Leading The Postherpetic Neuralgia (PHN) Market Growth?

Major companies operating in the postherpetic neuralgia (PHN) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Lexicon Pharmaceuticals Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Acasti Pharma Inc., Flexion Therapeutics Inc., Haisco Pharmaceutical Group Co. Ltd., Shanghai SIMR Biotechnology Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Region Is Projected To Lead The Postherpetic Neuralgia (PHN) Market During The Forecast Period?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2024. The regions covered in the postherpetic neuralgia (PHN) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Postherpetic Neuralgia (PHN) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24664&type=smp

Browse Through More Reports Similar to the Global Postherpetic Neuralgia (PHN) Market 2025, By The Business Research Company

Neuralgia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Breast Implants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Ocular Implants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795